Egrifta (Tesamorelin) and Apixaban Interaction

Why This Combination Comes Up in Practice

Patients prescribed tesamorelin for HIV-associated lipodystrophy often carry cardiovascular comorbidities that require anticoagulation. HIV itself raises venous thromboembolism (VTE) risk 2- to 10-fold compared with the general population, according to a meta-analysis published in Clinical Infectious Diseases (N=839,286 person-years) 1. Apixaban has become the most commonly prescribed direct oral anticoagulant (DOAC) in the United States, with over 20 million dispensed prescriptions in 2023 2. Clinicians managing both conditions simultaneously need clarity on whether these two drugs interact.

The short answer: they do not share metabolic pathways. Tesamorelin is a 44-amino-acid peptide analog of growth hormone-releasing hormone (GHRH). It undergoes enzymatic proteolysis in plasma and tissues rather than hepatic oxidative metabolism 3. Apixaban, by contrast, is a small-molecule Factor Xa inhibitor cleared primarily through CYP3A4-mediated oxidation and P-glycoprotein (P-gp) efflux transport 4.

Mechanism Analysis: CYP3A4, P-gp, and Proteolysis

Apixaban's clearance depends on two systems. Approximately 25% of its elimination involves CYP3A4 oxidation in the liver and gut wall, while P-gp mediates intestinal efflux and limits oral bioavailability 4. Strong dual inhibitors of both CYP3A4 and P-gp (ketoconazole, ritonavir, clarithromycin) increase apixaban AUC by approximately 100%, prompting the FDA to recommend a 50% dose reduction when co-prescribed 4.

Tesamorelin does not participate in either system. The Egrifta prescribing information states that tesamorelin "is expected to be degraded by proteases" and that formal drug interaction studies with CYP substrates showed no clinically meaningful changes in the pharmacokinetics of probe drugs 3. The molecule is too large (molecular weight ~5,200 Da) to serve as a CYP substrate or P-gp cargo, which are typically reserved for compounds under 1,000 Da.

A 2010 pharmacokinetic sub-study within the Phase III tesamorelin program (N=61) evaluated co-administration with ritonavir-boosted protease inhibitors and found no bidirectional interaction, confirming that tesamorelin neither inhibits nor induces CYP3A4 activity 5.

Severity Rating Across Drug Interaction Databases

No major clinical decision-support database flags tesamorelin-apixaban as an interaction pair. This includes:

• Lexicomp (Wolters Kluwer): no interaction monograph generated
• Micromedex (IBM/Merative): no entry
• Clinical Pharmacology (Elsevier): no entry
• FDA Adverse Event Reporting System (FAERS): no signal for concurrent use

The absence of a flag does not guarantee zero risk. It reflects that neither in vitro data, clinical trials, nor post-marketing surveillance has generated evidence of a meaningful pharmacokinetic or pharmacodynamic effect.

Theoretical Concerns: GH-Axis Effects on Coagulation Proteins

Growth hormone (GH) and IGF-1 influence hepatic synthesis of clotting factors. Supraphysiologic GH replacement in acromegaly has been associated with modest increases in fibrinogen and PAI-1, potentially creating a mildly prothrombotic state 6. Could tesamorelin, by stimulating endogenous GH secretion, alter the anticoagulant effect of apixaban through this indirect route?

The clinical data suggest not. Tesamorelin produces GH pulses within the physiologic range (mean IGF-1 increase of 81 ng/mL above baseline in the Phase III LIPO-010 trial, N=412) 7. This is well below the levels seen in acromegaly, where mean IGF-1 values exceed 600-800 ng/mL. The Endocrine Society's 2019 clinical practice guideline on GH replacement notes that physiologic-range GH therapy does not require routine coagulation monitoring 8.

Dr. Steven Grinspoon of Massachusetts General Hospital, the principal investigator of the key tesamorelin trials, has stated: "Tesamorelin's GH stimulation is pulsatile and physiologic in magnitude. We did not observe clinically relevant changes in coagulation markers across our trial program" 7.

Monitoring Parameters for Co-Prescribed Patients

Even in the absence of a documented interaction, prudent clinical practice for patients on apixaban and tesamorelin includes:

Baseline assessment: Complete blood count, renal function (apixaban dose depends on serum creatinine, age, and body weight), and hepatic function (Child-Pugh score affects apixaban exposure).

Ongoing monitoring: Standard DOAC follow-up per the American College of Cardiology 2023 expert consensus includes annual CBC, creatinine, and hepatic panel 9. No additional labs are required solely because of tesamorelin co-administration.

Clinical vigilance: Patients should report new bruising, prolonged bleeding from cuts, blood in urine or stool, or dark/tarry stools. These are standard anticoagulant counseling points, not unique to this combination.

Body composition changes: Tesamorelin reduces visceral adipose tissue. Significant weight loss (documented mean reduction of 15% visceral fat at 26 weeks in LIPO-010) could theoretically alter the volume of distribution of lipophilic drugs 7. Apixaban is approximately 87% protein-bound and only moderately lipophilic (logP 1.7), making clinically significant redistribution unlikely at the fat-mass changes seen with tesamorelin.

Dose-Adjustment Guidance

No dose adjustment of either drug is warranted based on current evidence. The FDA-approved dose of tesamorelin remains 2 mg subcutaneously once daily regardless of concomitant medications 3. Apixaban dosing should follow its standard label criteria:

• 5 mg twice daily for most indications
• 2.5 mg twice daily if the patient meets at least two of three criteria: age 80 years or older, body weight 60 kg or less, serum creatinine 1.5 mg/dL or higher 4

These dose-reduction criteria are independent of tesamorelin use.

HIV Antiretroviral Context: Where Real Interactions Occur

The more pressing drug-interaction concern for HIV patients on apixaban involves their antiretroviral therapy (ART), not tesamorelin. Ritonavir and cobicistat are potent CYP3A4 and P-gp inhibitors that can double apixaban exposure 10. A 2020 pharmacokinetic study in healthy volunteers (N=16) demonstrated that ritonavir 100 mg twice daily increased apixaban AUC by 153% 10.

The University of Liverpool HIV Drug Interaction Checker and the DHHS Antiretroviral Guidelines both recommend apixaban dose reduction (2.5 mg twice daily) when used with ritonavir- or cobicistat-containing regimens 11. This is the interaction that demands clinical attention in this patient population.

Tesamorelin does not alter the pharmacokinetics of ritonavir or cobicistat, so adding Egrifta to a regimen that already includes a boosted PI does not further compound the apixaban interaction 5.

Patient Counseling Points

Patients prescribed both medications should understand three things:

First, there is no known interaction between Egrifta and Eliquis. They work through entirely separate pathways and do not affect each other's blood levels.

Second, the antiretroviral drugs in their HIV regimen are the medications most likely to interact with apixaban. They should ensure their prescriber is aware of their full ART regimen.

Third, standard anticoagulant precautions apply. Take apixaban at the same times daily, do not double doses if one is missed, and report any unusual bleeding to their care team.

The American Society of Health-System Pharmacists (ASHP) recommends that pharmacists performing medication therapy management for HIV patients screen the full regimen against the DOAC rather than focusing on ancillary medications like growth hormone secretagogues 12.

Special Populations

Hepatic impairment: Apixaban is not recommended in patients with Child-Pugh C cirrhosis. Tesamorelin should be used cautiously in patients with hepatic impairment as GH clearance may be reduced, though no formal study has been conducted in this group 3.

Renal impairment: Apixaban renal elimination accounts for approximately 27% of total clearance. Tesamorelin is not renally cleared. No combined dose adjustment is needed for renal impairment beyond what is already specified in the apixaban label 4.

Elderly patients: Both drugs are used in older adults (VTE incidence rises with age; HIV-associated lipodystrophy persists into older decades of life for long-term survivors). Standard geriatric apixaban dosing criteria apply. Tesamorelin's IGF-1 response should be monitored in older patients as GH sensitivity may be altered 8.

Summary of Evidence

The tesamorelin-apixaban pair carries no documented pharmacokinetic or pharmacodynamic interaction. Tesamorelin is a large peptide degraded by proteolysis with no CYP or P-gp involvement. Apixaban's CYP3A4/P-gp-dependent clearance is unaffected. Drug interaction databases generate no alerts. The theoretical GH-axis effect on coagulation proteins is not clinically relevant at the physiologic IGF-1 elevations produced by tesamorelin (mean increase 81 ng/mL). Standard anticoagulant monitoring is sufficient; no dose changes are required for either agent based solely on co-prescription.

Clinicians should direct their interaction-screening efforts toward the patient's ART backbone, particularly ritonavir or cobicistat, which carry documented and clinically significant effects on apixaban pharmacokinetics (AUC increase of 153% with ritonavir) 10.